stockrowLegend Biotech Corporation Sponsored ADR
LEGN Healthcare Biotechnology
Legend Biotech Corporation Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 64.0% from fiscal 2024.
- Revenue
- +51.9%
- EPS
- +126.1%
- Free cash flow
- −26.8%
- Total debt
- −49.6%
Quarter to June 2026, against a year earlier
Follow LEGN
Alert me
Legend Biotech Corporation Sponsored ADR (LEGN) Net income
Legend Biotech Corporation Sponsored ADR's net income for fiscal 2025 was −$282.6M, compared with −$158.1M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$56.2M. Over the past ten years it has ranged from −$520.1M (fiscal 2023) to $0.00 (fiscal 2017); the current reading is higher than 56% of that period. Legend Biotech Corporation Sponsored ADR ranks 339th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$282.6M | — |
| FY2024 | −$158.1M | — |
| FY2023 | −$520.1M | — |
| FY2022 | −$445.7M | — |
| FY2021 | −$407.2M | — |
| FY2020 | −$307.6M | — |
| FY2019 | −$130.4M | — |
| FY2018 | −$1.6M | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $55.5M | — |
| Mar 2026 | −$53.1M | — |
| Dec 2025 | −$19.6M | — |
| Sep 2025 | −$39.0M | — |
| 27 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EWTX Edgewise Therapeutics, Inc. compare | $1.0B |
| LEGN Legend Biotech Corporation Sponsored ADR | −$56.2M |
| TVTX Travere Therapeutics, Inc. compare | −$121.5M |
| DNTH Dianthus Therapeutics, Inc. compare | −$202.1M |
| ERAS Erasca, Inc. compare | −$287.2M |
| RLAY Relay Therapeutics, Inc. compare | −$293.6M |
| DFTX Definium Therapeutics, Inc. compare | −$353.8M |
| COGT Cogent Biosciences, Inc. compare | −$377.2M |
| CRSP CRISPR Therapeutics AG compare | −$456.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on LEGN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement